Eris Lifesciences | inves4: Investing, News, Financial Planning

Awards and Recognitions (0)

Key Decisions by Management (0)

Promises/ Predictions by Management (0)

Key financial Decisions (0)

Accounting Observations (0)

Regulatory Actions (0)

Legal Cases (0)

Shareholders Activism (0)

Key Employee Resignations/ Hirings (0)

Customer Feedback (0)

Product/ Service Quality (0)

New Business/ Tie-Ups (0)

Discontinued Businesses (0)

Mergers/ Acquisitions (0)

Restructuring (0)

Fund Raises (0)

Shareholding Changes (0)

Employee Feedback (0)

Views by Analysts/ Investors (0)

Share Picks by Veterans (0)

Interesting Facts (0)

Important News (0)

Eris buying a part of dermatology portfolio of Glenmark

January 17, 2023

Eris Lifesciences is acquiring 9 dermatology brands from Glenmark Pharma. The brands are – Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands. The acquisition is ... Read more

Eris Lifesciences enters into insulin segment

December 4, 2021

Eris has formed a JV with MJ Biopharm for this purpose. Key points to note – Eris will hold 70% of the JV and MJ 30%. MJ is also getting ... Read more

Do you have something important to share about the Company?

0 Comments

Inline Feedbacks

View all comments